EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer.

@article{KamelReid2012EGFRTK,
  title={EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer.},
  author={Suzanne Kamel-Reid and Geoff Chong and Diana N. Ionescu and Anthony M. Magliocco and Alain Spatz and M Tsao and X Weng and Sam Young and T Zhang and Denis Souli{\'e}res},
  journal={Current oncology},
  year={2012},
  volume={19 2},
  pages={e67-74}
}
BACKGROUND Non-small-cell lung cancer (nsclc) tumours with activating mutations of the epidermal growth factor receptor (efgr) tyrosine kinase are highly sensitized to the effects of oral tyrosine kinase inhibitors such as gefitinib and erlotinib, suggesting the possibility of targeted treatment of nsclc based on EFGR mutation status. However, no standardized method exists for assessing the EGFR mutation status of tumours. Also, it is not known if available methods are feasible for routine… CONTINUE READING